1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Patient and lesional characteristics
Lesion Cohorta (n = 516)Patient Cohorta (n = 120)Median Survival (mo)
Age
    Median59.7 yr
    Range31–89 yr
Sex
    Male53 (44%)
    Female67 (56%)
Race
    Caucasian106 (88%)
    Other14 (12%)
Primary pathology
    NSCLCa175 (34%)47 (39%)11.8
    SCLCa20 (4%)6 (5%)6.8
    Breast116 (22%)18 (15%)12.3
    Melanoma123 (24%)24 (20%)13.7
    Renal51 (10%)11 (9%)8.5
    Colon13 (2.5%)6 (5%)13.0
    Other18 (3.5%)8 (7%)10.0
    Radiosensitiveb342 (66%)85 (71%)12.3
    Radioresistantc174 (34%)35 (29%)12.9
  • 

    Note:—NSCLCa indicates non-small cell lung carcinoma; SCLCa, small cell lung carcinoma.
  • 

    ↵a  Number of patients (%), unless otherwise specified.
  • 

    ↵b  Lung, breast, colon, other.
  • 

    ↵c  Melanoma, renal.